Aspirin resistance in South African Caucasian patients with thrombotic cerebrovascular events

Journal of the Neurological Sciences

Volumn 277, Issue 1-2, 2009, Pages 80-82

  Bernstein, P L ^a   Jacobson, B F ^a   Connor, M D ^b   Becker, P J ^c  

^a NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^b Faculty of Health Sciences   (South Africa)

^c Medical Research Council of South Africa (SAMRC)   (South Africa)

Author keywords

Aspirin resistance; Caucasian patients; South African; Thrombotic cerebrovascular events

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADRENALIN; ARACHIDONIC ACID; COLLAGEN;

ADULT; AGED; ARTICLE; ASPIRIN RESISTANCE; CAUCASIAN; CONTROLLED STUDY; DRUG RESISTANCE; HUMAN; MAJOR CLINICAL STUDY; OCCLUSIVE CEREBROVASCULAR DISEASE; PREVALENCE; PRIORITY JOURNAL; SOUTH AFRICA; STROKE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; TRANSIENT ISCHEMIC ATTACK;

ADULT; AGED; AGED, 80 AND OVER; ASPIRIN; DRUG RESISTANCE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INTRACRANIAL THROMBOSIS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PREVALENCE; RECURRENCE; SOUTH AFRICA; YOUNG ADULT;

EID: 58149280384     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2008.10.013     Document Type: Article

References (10)

1. Lopez A.D., Mathers C.D., Ezzati M., Jamison D.T., and Murray C.J. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 367 (2006) 1747-1757
2. Norman R., Bradshaw D., Schneider M., Pieterse D., and Groenewald P. Revised burden of disease estimates for the comparative risk factor assessment, South Africa, 2000 (2006), Medical Research Council, Cape Town
3. Bradshaw D., Schneider M., Dorrington R., Bourne D., and Laubscher R. South African cause-of-death profile in transition - 1996 and future trends. S Afr Med J 92 8 (2002) 618-623
4. Pestana J., Steyn K., Leiman A., and Hartzenberg G. The direct and indirect costs of cardiovascular disease in South Africa in 1991. S Afr Med J 86 6 (1996) 679-684
5. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ 324 (2002) 71-86
6. Gum, Kottke-Marchant K., Welsh P., White J., and Topol E. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41 6 (2003) 961-965
7. Helgason C., Bolin K., Hoff J., Winkler S., Mangat A., and Tortorice K. Development of aspirin resistance in persons with previous ischaemic stroke. Stroke 25 12 (1994) 2331-2336
8. Grotemeyer K.H., Scharafinski H.W., and Husstedt I.W. Two-year follow-up of aspirin responder and aspirin non-responder. A pilot-study including 180 post-stroke patients. Throm Res 71 (1993) 397-403
9. Crawford K.M., and Talbert R.L. Antiplatelet therapy in secondary stroke prevention. Expert Opin Pharmacother 2 10 (2001) 1609-1613
10. Weber A., Przytulski B., Schanz A., Hohlfeld T., and Schror K. Towards a definition of aspirin resistance: a typological approach. Platelets 13 (2002) 37-40